206 related articles for article (PubMed ID: 24892795)
1. Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.
Hauser A; Santos-Hoevener C; Meixenberger K; Zimmermann R; Somogyi S; Fiedler S; Hofmann A; Bartmeyer B; Jansen K; Hamouda O; Bannert N; Kuecherer C
PLoS One; 2014; 9(6):e98038. PubMed ID: 24892795
[TBL] [Abstract][Full Text] [Related]
2. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.
Duong YT; Qiu M; De AK; Jackson K; Dobbs T; Kim AA; Nkengasong JN; Parekh BS
PLoS One; 2012; 7(3):e33328. PubMed ID: 22479384
[TBL] [Abstract][Full Text] [Related]
3. Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.
Longosz AF; Serwadda D; Nalugoda F; Kigozi G; Franco V; Gray RH; Quinn TC; Eshleman SH; Laeyendecker O
AIDS Res Hum Retroviruses; 2014 Apr; 30(4):339-44. PubMed ID: 24083837
[TBL] [Abstract][Full Text] [Related]
4. Estimating False-Recent Classification for the Limiting-Antigen Avidity EIA and BED-Capture Enzyme Immunoassay in Vietnam: Implications for HIV-1 Incidence Estimates.
Shah NS; Duong YT; Le LV; Tuan NA; Parekh BS; Ha HTT; Pham QD; Cuc CTT; Dobbs T; Tram TH; Lien TTX; Wagar N; Yang C; Martin A; Wolfe M; Hien NT; Kim AA
AIDS Res Hum Retroviruses; 2017 Jun; 33(6):546-554. PubMed ID: 28193090
[TBL] [Abstract][Full Text] [Related]
5. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.
Konikoff J; Brookmeyer R; Longosz AF; Cousins MM; Celum C; Buchbinder SP; Seage GR; Kirk GD; Moore RD; Mehta SH; Margolick JB; Brown J; Mayer KH; Koblin BA; Justman JE; Hodder SL; Quinn TC; Eshleman SH; Laeyendecker O
PLoS One; 2013; 8(12):e82772. PubMed ID: 24386116
[TBL] [Abstract][Full Text] [Related]
6. Development of a New Limiting-Antigen Avidity Dot Immuno-Gold Filtration Assay for HIV-1 Incidence.
Gao Z; Yan H; Feng X; Wu L; Qiu M; Xing W; Zhang G; Zhang Z; Jiang Y
PLoS One; 2016; 11(8):e0161183. PubMed ID: 27513563
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Performance of Three Biomarker Assays for Recent HIV Infection Using a Well-Characterized HIV-1 Subtype C Incidence Cohort.
Gonese E; Kilmarx PH; van Schalkwyk C; Grebe E; Mutasa K; Ntozini R; Parekh B; Dobbs T; Duong Pottinger Y; Masciotra S; Owen M; Nachega JB; van Zyl G; Hargrove JW
AIDS Res Hum Retroviruses; 2019 Jul; 35(7):615-627. PubMed ID: 30938164
[TBL] [Abstract][Full Text] [Related]
8. Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes.
Duong YT; Kassanjee R; Welte A; Morgan M; De A; Dobbs T; Rottinghaus E; Nkengasong J; Curlin ME; Kittinunvorakoon C; Raengsakulrach B; Martin M; Choopanya K; Vanichseni S; Jiang Y; Qiu M; Yu H; Hao Y; Shah N; Le LV; Kim AA; Nguyen TA; Ampofo W; Parekh BS
PLoS One; 2015; 10(2):e0114947. PubMed ID: 25710171
[TBL] [Abstract][Full Text] [Related]
9. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.
Wendel SK; Mullis CE; Eshleman SH; Blankson JN; Moore RD; Keruly JC; Brookmeyer R; Quinn TC; Laeyendecker O
PLoS One; 2013; 8(2):e55525. PubMed ID: 23437058
[TBL] [Abstract][Full Text] [Related]
10. Estimating HIV incidence in the Akwa Ibom AIDS indicator survey (AKAIS), Nigeria using the limiting antigen avidity recency assay.
Negedu-Momoh OR; Balogun O; Dafa I; Etuk A; Oladele EA; Adedokun O; James E; Pandey SR; Khamofu H; Badru T; Robinson J; Mastro TD; Torpey K
J Int AIDS Soc; 2021 Feb; 24(2):e25669. PubMed ID: 33619853
[TBL] [Abstract][Full Text] [Related]
11. Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.
Longosz AF; Morrison CS; Chen PL; Arts E; Nankya I; Salata RA; Franco V; Quinn TC; Eshleman SH; Laeyendecker O
J Acquir Immune Defic Syndr; 2014 Apr; 65(4):390-6. PubMed ID: 24583613
[TBL] [Abstract][Full Text] [Related]
12. Field Validation of Limiting-Antigen Avidity Enzyme Immunoassay to Estimate HIV-1 Incidence in Cross-Sectional Survey in Swaziland.
Duong YT; Dobbs T; Mavengere Y; Manjengwa J; Rottinghaus E; Saito S; Bock N; Philip N; Justman J; Bicego G; Nkengasong JN; Parekh BS
AIDS Res Hum Retroviruses; 2019 Oct; 35(10):896-905. PubMed ID: 31204867
[TBL] [Abstract][Full Text] [Related]
13. The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx.
Huik K; Soodla P; Pauskar M; Owen SM; Luo W; Murphy G; Jõgeda EL; Kallas E; Rajasaar H; Avi R; Masciotra S; Lutsar I;
PLoS One; 2019; 14(5):e0217048. PubMed ID: 31125356
[TBL] [Abstract][Full Text] [Related]
14. Decision tree for accurate infection timing in individuals newly diagnosed with HIV-1 infection.
Verhofstede C; Fransen K; Van Den Heuvel A; Van Laethem K; Ruelle J; Vancutsem E; Stoffels K; Van den Wijngaert S; Delforge ML; Vaira D; Hebberecht L; Schauvliege M; Mortier V; Dauwe K; Callens S
BMC Infect Dis; 2017 Nov; 17(1):738. PubMed ID: 29187159
[TBL] [Abstract][Full Text] [Related]
15. Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.
Kirkpatrick AR; Patel EU; Celum CL; Moore RD; Blankson JN; Mehta SH; Kirk GD; Margolick JB; Quinn TC; Eshleman SH; Laeyendecker O
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):756-62. PubMed ID: 26988426
[TBL] [Abstract][Full Text] [Related]
16. Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda.
Mullis CE; Munshaw S; Grabowski MK; Eshleman SH; Serwadda D; Brookmeyer R; Nalugoda F; Kigozi G; Kagaayi J; Tobian AA; Wawer M; Gray RH; Quinn TC; Laeyendecker O
AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1146-50. PubMed ID: 23641870
[TBL] [Abstract][Full Text] [Related]
17. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.
Laeyendecker O; Brookmeyer R; Mullis CE; Donnell D; Lingappa J; Celum C; Baeten JM; Campbell MS; Essex M; de Bruyn G; Farquhar C; Quinn TC; Eshleman SH;
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1177-83. PubMed ID: 22283149
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the false recent classification rates of multiassay algorithms in estimating HIV type 1 subtype C incidence.
Moyo S; LeCuyer T; Wang R; Gaseitsiwe S; Weng J; Musonda R; Bussmann H; Mine M; Engelbrecht S; Makhema J; Marlink R; Baum MK; Novitsky V; Essex M
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):29-36. PubMed ID: 23937344
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma.
Schlusser KE; Pilcher C; Kallas EG; Santos BR; Deeks SG; Facente S; Keating SM; Busch MP; Murphy G; Welte A; Quinn T; Eshleman SH; Laeyendecker O
PLoS One; 2017; 12(2):e0172283. PubMed ID: 28231277
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a BioRad Avidity assay for identification of recent HIV-1 infections using dried serum or plasma spots.
Hauser A; Heiden MA; Meixenberger K; Han O; Fiedler S; Hanke K; Koppe U; Hofmann A; Bremer V; Bartmeyer B; Kuecherer C; Bannert N
J Virol Methods; 2019 Apr; 266():114-120. PubMed ID: 30738741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
